Antimicrobial resistance: Implications for managing respiratory failure

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 2, 1997, Pages 159-169

  Chenoweth, Carol ^a   Lynch III, Joseph P ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM; DISEASE TRANSMISSION; DRUG EFFECT; HUMAN; MULTIDRUG RESISTANCE; REVIEW; RISK FACTOR;

BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; RISK FACTORS;

EID: 0031089949     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199703000-00013     Document Type: Article

References (94)

1. Doern G: Trends in antimicrobial susceptibility of bacterial pathogens in the respiratory tract. Am J Med 1995, 99(6B):3S-7S.
2. Jacoby G: Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin Infect Dis 1994, 18:951-957.
3. Jones R: Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996, 100(6A):3S-12S.
4. Gold H, Moellering R Jr: Antimicrobial drug resistance. N Engl J Med 1996, 335:1445-1453. This review of antimicrobial resistance patterns and mechanisms of developing resistance to various antibiotics discusses in detail extended-spectrum β-lactamases (among enteric gram-negative bacteria), penicillin-resistant pneumococci, and VRE.
5. Flaherty J, Weinstein R: Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. Infect Control Hosp Epidemiol 1996, 17:236-248. This paper provides a complete summary of infection control techniques and antibiotic control measures for the prevention of emergence and spread of resistant organisms in ICUs.
6. Itokazu G, Quinn J, Bell-Dixon C, Kahan F, Weinstein R: Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996, 23:779-784. In this review of antimicrobial susceptibilities of gram-negative bacilli isolated from 396 ICUs from 45 states between 1990 and 1993, resistance to third-generation cephalosporins was found to be an emerging problem. Risk factors for ceftazidime resistance were identified.
7. Livermore D: β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995, 8:557-584.
8. Fraimow H, Abbrutyn E: Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 1995, 9:497-530.
9. Meyer K, Urban C, Eagan J, Berger B, Rahal J: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993, 119:353-358.
10. Rice L, Carias L, Bonomo R, Schlaes D: Molecular genetics of resistance to both ceftazidime and β-lactam-β-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to β-lactam therapy. J Infect Dis 1996, 173:151-158.
11. Fink M, Snydman D, Niederman M, Leeper K Jr: Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilasting. Antimicrob Agents Chemother 1994, 38(3):547-557.
12. Lynch JP III: Combination antibiotic therapy is appropriate for nosocomial pneumonia in the intensive care unit. Semin Respir Infect 1993, 8:268-284.
13. Richard P, Le Floch R, Chamox C, Pannier M, Espaze E, Richet H: Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J Infect Dis 1994, 170:377-383.
14. Rello J, Ausina V, Ricart M, Castella J, Prats G: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993, 104:1230-1235.
15. Fagon J, Chastre J, Hance A, Montravers P, Novara A, Gibert C: Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993, 94:281-288.
16. Bartlett J, Mundy L: Community-acquired pneumonia. N Engl J Med 1995, 333:1618-1623.
17. Hoffman J, Cetron M, Farley M, Baughman W: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995, 333:481-486. In this prospective study of invasive pneumococcal infections in Atlanta, Georgia from January through October 1994, of 431 isolates of S. pneumoniae, 25% were resistant to penicillin (7% were highly resistant). The rates of resistance to other antibiotics was also high, including trimethoprim/sulfamethoxazole (26%), erythromycin (15%), cefotaxime (9%), and multiple drugs (25%). Six serotypes (14, 6B, 9V, 23F, 19A, 6A) accounted for over 85% of isolates resistant to penicillin, cefotaxime, or multiple drugs. Thirteen of 15 with high-level resistance to penicillin and cefotaxime were serotype 23F.
18. Butler J, Hofman J, Cetron M, Elliott J: The continued emergence of drug-resistant pneumococcal infections in the United States. J Infect Dis 1996, 174:986-993. This was a national surveillance study of 740 isolates of S. pneumoniae from 12 hospitals in 11 states during 1993 and 1994. Overall, 14% were penicillin nonsusceptible (MIC 0.1 μg/mL or more); an additional 3.2% were penicillin resistant (MIC 2 μg/mL or more). Penicillin resistance was higher in children younger than 6 years of age. Penicillin nonsusceptibility represented 15 serotypes, but 89% were in the 23-valent pneumococcal vaccine.
19. Sanders C, Sanders W Jr: β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992, 15:824-839.
20. Chow J, Fine M, Shlaes: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
21. Rice L, Eckstein E, DeVente J, Shlaes D: Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996, 23:118-124. The rate of ceftazidime resistance among K. pneumoniae isolated from patients at one hospital increased from 6% to 28% between 1993 and 1994. Rates of resistance correlated with prior use of ceftazidime. Plasmid patterns suggest that most strains originated from a single clone. Ceftazidime resistance decreased following restricted use of ceftazidime and increased use of piperacillin/tazobactam.
22. Burwen D, Banerjee S, Gaynes R: Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994, 170:1622-1625.
23. Gaynes R, Culver D: Resistance to imipenem among selected gram negative bacilli in the United States. Infect Control Hosp Epidemiol 1992, 13:10-14.
24. Livermore D: Carbapenemases. J Antimicrobial Chemother 1992, 29:609-613.
25. Senda K, Arakawa Y, Nakashima K, Ito H: Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996, 40:349-353.
26. Barry A, Pfaller M, Fuchs P, Packer R: In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994, 38:2419-2425.
27. Plouffe J, Breiman R, Facklam R: Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA 1996, 275:194-198.
28. Oethinger M, Conrad S, Kaifel K, Cometta A: Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother 1996, 40:387-392.
29. Coronado V, Edwards J, Culver D, Gaynes R, System TNNIS: Ciprofloxacin resistance among Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995, 16:71-75.
30. Ball P: Is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as a prophylaxis? Clin Infect Dis 1995, 20:561-563.
31. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F: Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995, 20:557-560. This is the first report of the emergence of fluoroquinolone resistance in E. coli related to the use of norfloxacin prophylaxis.
32. Jones R, Reller B, Rosati L, Erwin M: Ofloxacin, a new broad-spectrum fluoroquinolone: results from a multicenter, national, comparative activity surveillance study. Diagn Microbiol Infect Dis 1992, 15:425-434.
33. Klepser M, Patel K, Nicolau D, Quintiliani R, Nightingale C: Comparison of the bactericidal activities of ofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995, 39:2503-2510.
34. Bergogne-Berezin E, Towner K: Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9:148-165. In this comprehensive review of the emergence of Acinetobacter spp as significant nosocomial pathogens, risk factors for the development of infections are highlighted.
35. Cisneros J, Reyes M, Pachon J, Becerril B, Caballero F: Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996, 22:1026-1032.
36. Lortholary O, Fagon J, Hoi A, Slama M: Nosocomial acquisition of multiresistant Acinetobacter baumanii: risk factors and prognosis. Clin Infect Dis 1995, 20:790-796.
37. Seifert H, Strate A, Pulvererf G: Nosocomial bacteremia due to acinetobacter baumanii: clinical features, epidemiology, and predictors of mortality. Medicine 1995, 74:340-349.
38. Campbell G, Niederman M, Broughton W, Craven D: Hospital acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement Am J Respir Crit Care Med 1996, 153:1711-1725. This consensus statement of the American Thoracic Society reviews hospital-acquired pneumonia, including pathogenesis, risk factors, microbiology (salient pathogens), diagnosis, therapy, and prevention. The article presents specific recommendations to diagnose and treat hospital-acquired pneumonia and assess reponse to therapy.
39. Dijkshoorn L, Auchen P, Gerner-Schmidt P, Janssen P: Comparison of outbreak and nonoutbreak Acinetobacter baumanii strains by genotypic and phenotypic methods. J Clin Microbiol 1996, 34:1519-1525.
40. Corbella X, Pujol M, Ayats J, Montserrat S: Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumanii. Clin Infect Dis 1996, 23:329-334.
41. Perilli M, Felici A, Oratore A, Cornaglia G: Characterization of the chromosomal cephalosporinases produced by Acinetobacter Iwoffi and Acinetobacter baumanii clinical isolates. Antimicrob Agents Chemother 1996, 40:715-719.
42. Vila J, Marcos A, Marco F: In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter species. Antimicrob Agents Chemother 1993, 37:138-141.
43. Go E, Urban C, Burns J: Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994, 344:1329-1332.
44. Hamill R, Houston E, Georghiou P, Wright C: An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995, 122:762-766.
45. Spencer R: The emergence of epidemic, multiple antibiotic-resistant Stenotrohomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995, 308:453-464.
46. Arpin C, Coze C, Rogues A, Gachie A, Bebear C, Quentin C: Epidemiological study of an outbreak due to multidrug-resistant Enterobacter aerogenes in a medical intensive care unit. J Clin Microbiol 1996, 34:2163-2169.
47. Lucet J, Chevret S, Decre D, Vanjak D: Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996, 22:430-436. This is a prospective study in an ICU where extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLPE) were endemic. The risk for acquiring ESBLPE increased during the ICU stay from 4% in the 1st week to 24% by the 4th week. Urinary catheterization and arterial cannulation were independent risk factors for acquiring ESBLPE. A single strain was responsible for most cases (by DNA macrorestriction analysis).
48. Davin-Regli A, Monnet D, Saux P, Bosi C: Molecular epidemiology of Enterobacter aerogenes acquisition: one-year prospective study in two intensive care units. J Clin Microbiol 1996, 34:1474-1480. Molecular typing confirms the importance of patient-to-patient transmission of Enterobacter spp in the ICU.
49. Fekete T, Tumah H, Woodwell J, Satishchandran V, Truant A, Axelrod P: Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 antimicrobial agents in a tertiary-care university hospital. Am J Med 1996, 100(S6A):20S-25S. This study compares antimicrobial resistance in major gram-negative pathogens from a single tertiary care center and evaluates the activity of cefipime against resistant organisms.
50. Sanders W, Tenney J, Kessler R: Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996, 23:454-461.
51. Medeiros A: Nosocomial outbreaks of multiresistant bacteria: extended-spectrum β-lactamases have arrived in North America. Ann Intern Med 1993, 119:428-429.
52. Rello J, Ricart M, Ausina V, Net A, Prats G: Pneumonia due to Haemophilus influenzae among mechanically ventilated patients: incidence, outcome, and risk factors. Chest 1992, 102:1562-1565.
53. Farley M, Stephens D, Brachman P, Harvey C: Invasive Haemophilus influenzae disease in adults: a prospective, population-based surveillance. Ann Intern Med 1992, 116:806-812.
54. Scriver S, Walmsley S, Kau C: Determination of antimicrobial susceptibilities of Canadian isolates of Hemophilus influenzae and characterization of β-lactamases. Antimicrob Agents Chemother 1994, 38:1678-1680.
55. Wood G, Johnson B, McCormack J: Moraxella catarrhalis: pathogenic significance in respiratory tract infections treated by community practioners. Clin Infect Dis 1996, 22:632-636.
56. Leeper K, Torres A: Community-acquired pneumonia in the intensive care unit. Clin Chest Med 1995, 16:155-170.
57. Brewer S, Wunderink R, Jones C, Leeper K: Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996, 109:1019-1029.
58. Chen H, Yan M, Livermore D: Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995, 43:300-309.
59. Muder R, Harris A, Muller S, Edmond M, Chow J: Bacteremia due to Stenotrophomonoas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996, 22:508-512.
60. Villarino M, Stevens L, Schable B, Mayers G: Risk factors for epidemic Xanthomonas malthophila infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992, 13:201-206.
61. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K: A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994, 38:624-627.
62. Poulos C, Matsumura S, Willey B, Low D, McGeer A: In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 1995, 39:2220-2223.
63. Pankuch G, Jacobs M, Rittenhouse S, Appelbaum P: Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother 1994, 38:2317-2322.
64. Rello J, Torres A, Ricart M, Valles J, Gonzalez J, Artigas A, Rodriguez-Roisin R: Ventilator-associated pneumonias by Staphylococcus aureus: Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994, 150:1545-1550.
65. Mulligan M, Murray-Leuisure K, Ribenr B, Standiford H: Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993, 94:313-328.
66. Moreno F, Crisp C, Jorgenson J, Patterson J: Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995, 21:1308-1312.
67. Gaynes R, Culver D, Horan T, Henderson T, et al.: Trends in methicillin-resistant Staphylococcus aureus in the United States. Infect Dis Clin Pract 1994, 2:452-455.
68. Boyce J, Jackson M, Pugliese G, Batt M: Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospital and nursing facilities. Infect Control Hosp Epidemiol 1994, 15:105-115.
69. Iwahara T, Ichiyama S, Nada T, Shimokata K, Nakashima N: Clinical and epidemiologic investigations of nosocomial pulmonary infections of nosocomial pulmonary infections caused by methicillin resistant Staphylococcus aureus. Chest 1994, 105:826-846.
70. Pujol M, Pena C, Pallares R, Ariza J: Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996, 100:509-516. This study provides convincing evidence that MSRA represents a greater threat of infection to patients than MSSA.
71. Romero-Vivas J, Rubio M, Fernandez C, Picazo J: Mortality associated with nosocomial bactermia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995, 21:1417-1423.
72. Centers for Disease Control and Prevention: Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HIPAC). MMWR Morbid Mortal Wkly Rep 1995, 44(RR-12):1-13. This article presents the first national guidelines outlining measures to be used by health care facilities to reduce transmission of VRE. The guidelines for restriction of vancomycin are included.
73. Bedos J, Chevret S, Chastang C, Geslin P, Regnier B: Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis 1996, 22:63-72.
74. Barnes D, Whittier S, Gilligan P, Soares S: Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis 1995, 171:890-896.
75. Doern G, Brueggemann A, Holley H Jr, Rauch A: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center National Surveillance Study. Antimicrob Agents Chemother 1996, 40:1208-1213. This nationwide study of the prevalence of resistant S. pneumoniae highlights the alarming increase in penicillin resistance from multiple sites.
76. Lee H, Park J, Jang S, Kim J, Kim E, Choi K: High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a University Hospital in Korea. Clin Infect Dis 1995, 20:826-835.
77. Moreno S, Carcia-Leoni M, Cercenado E, Diaz M: Infections caused by erythromycin resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995, 20:1195-1200. In this prospective study of resistance of S. pneumoniae isolated from hospitalized patients from a single hospital in Madrid, Spain, the incidence of erythromycin resistance (MIC greater than 1 μg/mL) increased from 7.6% in 1988 to 15.2% in 1992. Age less than 5 years and nosocomial acquisition were independent factors associated with erythromycin resistance. Ninety-four percent of macrolide-resistant strains displayed resistance to multiple antibiotics. Four of six patients with erythromycin-resistant strains were cured with erythromycin alone. Nine patients with pneumonia caused by erythromycin-resistant pneumococci were treated with ceftriaxone; all nine were cured.
78. Pallares R, Linares J, Vadillo M, Cabellos C: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480. During this 10-year prospective study of 504 adults with pneumococcal pneumonia in Barcelona, Spain, resistance to penicillin, cephalosporins, and erythromycin increased significantly. Overall, 29% of isolates were resistant to penicillin; 6% were resistant to ceftriaxone or cefotaxime. When other predictors of mortality were taken into account, mortality was no higher with penicillin-resistant or cephalosporin-resistant strains.
79. Coffey T, Dowson C, Daniels M, Spratt B: Genetics and molecular biology of β-lactam-resistant pneumococci. Microb Drug Resist 1995, 1:29-34.
80. Hedlung J, Svenson S, Kalin M, Henrichsen J: Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Clin Infect Dis 1995, 21:948-953.
81. Nissinen A, Leinonen M, Huovinen P, Herva E: Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990. Clin Infect Dis 1995, 20:1275-1280.
82. Breiman R, Butler J, Tenover F, Elliot J, Facklam R: Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994, 271:1831-1835.
83. Nava J, Bella F, Garau J: Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis 1994, 19:884-890.
84. Reichler M, Rakowsky J, Slacikova M: Spread of multi-drug resistant Streptococcus pneumoniae among hospitalized children in Slovakia. Antimicrob Agents Chemother 1996, 173:374-379.
85. McDougal L, Rasheed J, Biddle J, Tenowver F: Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1995, 39:2282-2288.
86. Jones R, Sader H, Erwin M, Anderson S, the Enterococcus Study Group: Emerging multiple resistant enterococci among clinical isolates: I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis 1995, 21:85-93.
87. Low D, Willey B, McGeer A: Multidrug-resistant enterococci: a threat to the surgical patient. Am J Surg 1995, 169(S5A):8S-12S.
88. Centers for Disease Control and Prevention: Nosocomial enterococci resistant to vancomycin United States, 1989-1993. MMWR Morbid Mortal Wkly Rep 1993, 42:595-597.
89. Morris J Jr, Shay D, Hebden J, McCarter R Jr: Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995, 123:250-259. This study provides a description of a persistent outbreak of VRE and the control measures that were successful in decreasing the prevalence of vancomycin resistance. It provides the first evidence that vancomycin restriction can help reduce the prevalence of vancomycin-resistant organisms.
90. Tornieporth M, Roberts R, John J, Hafner A, Riley L: Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996, 23:767-772.
91. Edmond M, Ober J, Weinbaum D, Pfaller M: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20:1126-1133.
92. Bonten M, Gaillard C, VanTiel F, VanderGeest S, Stobberingh E: Colonization and infection with Enterococcus faecalis in intensive care units: the role of antimicrobial agents. Antimicrob Agents Chemother 1995, 39:2783-2786.
93. Slaughter S, Hayden M, Nathan C: A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996, 125:448-456.
94. Quayle J, Landman D, Saurina G, Atwood E, Ditore V, Patel K: Manipulation of a hospital formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996, 23:1020-1025. Infection control practices were not successful in limiting outbreaks of VRE at one tertiary care center. Restricting the use of cefotaxime, clindamycin, and vancomycin and adding extended-spectrum penicillins with β-lactamase inhibitors to replace third-generation cephalosporins were associated with a reduction in fecal colonization with VRE from 47% to 15%.